The agreement is aimed at delivering drug development candidates directed to a key respiratory target of interest to Almirall.
As per the collaboration, BioFocus will apply its integrated drug discovery capabilities whilst Almirall will bring in respiratory specific knowhow to the joint experimental effort.
The value of this collaboration to BioFocus is expected to reach E7.5m.
Almirall R&D executive director Bertil Lindmark said that they selected BioFocus for this alliance because of the excellent technology and scientific fit between both the companies.